太阳集团1088vip十周年院慶系列活動——藥學前沿大講堂第154講
Safety Evaluation Strategies in Early Drug Development （藥物早期發展中的安全評價策略）
發布人：高級管理員
發布日期：2013-09-11
主題
Safety Evaluation Strategies in Early Drug Development （藥物早期發展中的安全評價策略）
活動時間
-
活動地址
中山大學東校區太阳集团1088vip112會議室
主講人
徐尚志博士
主持人
皮榮标 教授
太阳集团1088vip十周年院慶系列活動——
藥學前沿大講堂第154講
題 目： Safety Evaluation Strategies in Early Drug Development
（藥物早期發展中的安全評價策略）
報告人：徐尚志博士（Shang-Zhi Xu, PhD）
VP, Preclinical Study and Drug Registration; Director of Safety Evaluation Center at Curegenix
主持人：皮榮标 教授 太阳集团1088vip
時 間： 2013年09月13日（周五）上午10：30
地 點： 中山大學東校區太阳集团1088vip112會議室
報告人簡介：
Shang-Zhi Xu graduated from An-hui Medical University in 1984 with a BS in Human Medicine and completed his Ph.D in 1996 at Pharmacology &Toxicology from Chinese Academy of Medical Science. He then pursued a post-doctoral fellowship at the Scripps Research Institute in La Jolla, California before joining Alcorn State University in Alcorn, Mississippi and Mayo Clinic in Rochester, Minnesota as a assistant professor in 2002 and 2005, respectively. He moved to WuxiApptec in St. Paul as study director in Toxicology in 2007 and served as a director of Toxicology in Frontier Biosciences, Inc in Germantown in 2011. In March 2012, he was appointed as a VP, Preclinical study and Drug registration, director of Safety Evaluation Center at Curegenix.
Shang-Zhi Xu has more than 15 years experience of Pharmacology & Toxicology preclinical studies in Rodents. He published over 10 papers in peer reviewed journals and won DHHS/NIH/NCRR (NIH research grant, 2002-4 at Alcorn State University), NIH T32 Fellowship (2005-7, Mayo Clinic), GEM Award (WuXiApptec, Inc., 2008) and DABT (Diplomate, American Board of Toxicology). As a global and professional Toxicologist, DABT certified, he is an expert in GLP regulations and preclinical studies in SFDA(China),OECD, ICH, FDA red book, and helps to complete preclinical study package for filing IND. Every year he led 2-3 groups to complete 1 Million US $ or 5 Million RMB projects. Drive anti-tumor drug discovery pipeline in preclinical studies and IND submission, NDA and drug registration, including PARP1 inhibitor, WNT inhibitor, and MET enzyme inhibitors etc.
歡迎廣大師生踴躍參加！